SLC5A2 and chronic kidney disease: However, according to the KDIGO 2020 guideline recommendation of using SGLT2 inhibitors in managing patients with T2DM, CKD, and those with an eGFR ≥ 30 mL/min/1.73 m2, and extending the indications for an SGLT2 inhibitor in nondiabetic CKD patients, recognition of the importance of SGLT2 inhibitors in the CKD prediction model has been increasing [34].